Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA INVESTIGATING RECALLED ELDEPRYL LOT

Executive Summary

FDA INVESTIGATING RECALLED ELDEPRYL LOT because of "lack of assurance of product origin and authenticity." A Class II recall of the MAO-B inhibitor for Parkinson's disease began in September. Somerset Pharmaceuticals, the 50/50 Mylan/Circa joint venture that markets Eldepryl (selegiline), said Jan. 4 that some of the recalled product is "definitely counterfeit."

Latest Headlines
See All
UsernamePublicRestriction

Register

PS023862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel